Maxim Group Increases Tekmira Pharmaceuticals Corp Price Target to $31.00 (TKMR)
Stock analysts at Maxim Group boosted their price target on shares of Tekmira Pharmaceuticals Corp (NASDAQ:TKMR) from $17.00 to $31.00 in a report issued on Monday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 61.88% from the stock’s previous close.
Separately, analysts at Stifel Nicolaus initiated coverage on shares of Tekmira Pharmaceuticals Corp in a research note on Friday, January 31st. They set a “buy” rating and a $19.00 price target on the stock.
Tekmira Pharmaceuticals Corp (NASDAQ:TKMR) opened at 19.15 on Monday. Tekmira Pharmaceuticals Corp has a 1-year low of $4.18 and a 1-year high of $22.14. The stock has a 50-day moving average of $13.3 and a 200-day moving average of $8.83.
Tekmira Pharmaceuticals Corp (NASDAQ:TKMR) last issued its quarterly earnings data on Wednesday, December 18th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.05. On average, analysts predict that Tekmira Pharmaceuticals Corp will post $-0.67 earnings per share for the current fiscal year.
Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (NASDAQ:TKMR).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.